Wu D, Zhao Z, Liu H, Fu K, Ji Y, Ji W;LiY
A Market in Transition The current landscape can be summarised simply: GLP-1s remain clinically and commercially dominant But the innovation spotlight has shifted to what comes next This evolving balance was a key consideration when shaping this years agenda
For those weighing retatrutide against other options, the semaglutide vs tirzepatide comparison provides useful context, as does the retatrutide vs tirzepatide dosage chart for side-by-side dose analysis
Glucagon-Like Peptide-1. PubChem , National Center for Biotechnology Information, National Library of Medicine, Mayer JP, et al
The strategies discussed earlier for stabilizing blood sugar apply doubly for brain fog
Maintenance phase Weight regain after stopping retatrutide is common, though not universal